An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain

BMC Pulmonary Medicine

Research

Lisa Miners¹  Katy M. E. Turner¹  Susie Huntington¹  Elisabeth Adams¹  Nathaniel Lee² 

[1]Aquarius Population Health, Unit 29 Tileyard Studios, N7 9AH, London, UK

[2]Hospital for Tropical Diseases, University College London Hospital NHS Foundation Trust, London, UK

关键词: Community-acquired pneumonia;    Diagnostics;    Microbiology;    COVID-19;    Influenza;    Legionella;    Antimicrobial stewardship;   

DOI  :  10.1186/s12890-023-02516-2

 received in 2022-12-01, accepted in 2023-06-09,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundOn admission to hospital, patients with community-acquired pneumonia (CAP), undergo extensive diagnostic testing. Two high-throughput laboratory-based PCR panels which return a result in 5.5 hours (h) have been developed to test for pathogens commonly associated with upper (Respiratory 1 Panel) and lower (Respiratory 3 Panel) respiratory tract infections (GeneFirst, Oxford). These could replace multiple diagnostic tests currently used.MethodsAn online survey, completed by senior clinicians in the UK, France and Spain, was used to collect data on the diagnostic testing of immunocompetent and immunocompromised adults admitted to hospital with CAP, including the cost of diagnostics. Data were used to inform a cost-comparison model. For each country, the average cost of diagnostic testing per patient was calculated separately for immunocompetent and immunocompromised patients.The model compared three testing strategies with standard of care (SoC). In the Panel 1 strategy, the Respiratory 1 Panel was used for patients that would otherwise have tests which could be replaced by Respiratory 1 Panel, equivalent strategies for Respiratory 3 Panel and for both panels combined were assessed.ResultsIn total, 48 surveys were completed (UK = 17; France = 15; Spain = 16). Compared with SoC, the Panel 1 + 3 strategy was most favourable, resulting in cost savings for immunocompetent and immunocompromised patients respectively, of €22.09 (£18.50) and €26.12 (£21.88) in the UK, €99.60 and €108.77 in France and €27.07 and €51.87 in Spain.ConclusionIn all three countries, the use of these respiratory panels could reduce the average cost of diagnostics used for patients admitted to hospital with CAP.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_37_Article_IEq133.gif